Company profile

Richard A. Gonzalez
Incorporated in
Fiscal year end
IRS number

ABBV stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


8 May 20
8 Jul 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 8.62B 8.7B 8.48B 8.26B
Net income 3.01B 2.8B 1.88B 741M
Diluted EPS 2.02 1.88 1.26 0.49
Net profit margin 34.92% 32.18% 22.22% 8.98%
Operating income 3.6B 3.96B 2.62B 3.4B
Net change in cash 1.22B 29.28B 5.48B 275M
Cash on hand 41.14B 39.92B 10.65B 5.17B
Cost of revenue 1.94B 2.01B 1.92B 1.82B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 33.27B 32.75B 28.22B 25.64B
Net income 7.88B 5.69B 5.31B 5.95B
Diluted EPS 5.28 3.66 3.3 3.63
Net profit margin 23.69% 17.36% 18.82% 23.22%
Operating income 12.98B 6.38B 9.55B 9.34B
Net change in cash 32.64B -2.01B 4.2B -3.3B
Cash on hand 39.92B 7.29B 9.3B 5.1B
Cost of revenue 7.44B 7.72B 7.04B 5.83B

Financial data from AbbVie earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
30 Jun 20 Alpern Robert J Stock Equivalent Units Common Stock Grant Aquire A No 98.18 71 6.97K 7,353
30 Jun 20 Liddy Edward M Stock Equivalent Units Common Stock Grant Aquire A No 98.18 335 32.89K 26,288
30 Jun 20 Edward J Rapp Stock Equivalent Units Common Stock Grant Aquire A No 98.18 350 34.36K 18,108
12 May 20 Jeffrey Ryan Stewart Common Stock, $0.01 par value Sell Dispose S No 90.0022 23,024 2.07M 52,760
8 May 20 Burnside William H.L. Common Stock, $0.01 par value Grant Aquire A No 0 2,333 0 19,881
60.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2080 2100 -1.0%
Opened positions 148 308 -51.9%
Closed positions 168 99 +69.7%
Increased positions 938 783 +19.8%
Reduced positions 770 768 +0.3%
13F shares
Current Prev Q Change
Total value 80.81B 94.47B -14.5%
Total shares 1.06B 1.06B -0.2%
Total puts 19.45M 22.2M -12.4%
Total calls 16.64M 19.3M -13.8%
Total put/call ratio 1.2 1.2 +1.6%
Largest owners
Shares Value Change
Vanguard 125.6M $9.57B +2.5%
BLK BlackRock 101.38M $7.72B +2.8%
STT State Street 68.23M $5.2B -0.9%
Capital Research Global Investors 49.23M $3.75B -43.2%
N Price T Rowe Associates 42.93M $3.27B +52.8%
FMR 35.01M $2.67B -13.0%
Geode Capital Management 25.77M $1.96B +5.5%
JPM JPMorgan Chase & Co. 22.44M $1.71B +25.0%
NTRS Northern Trust 20.34M $1.55B +4.6%
BK Bank Of New York Mellon 18.59M $1.42B +23.0%
Largest transactions
Shares Bought/sold Change
Capital Research Global Investors 49.23M -37.37M -43.2%
Norges Bank 0 -15.28M EXIT
N Price T Rowe Associates 42.93M +14.84M +52.8%
FMR 35.01M -5.23M -13.0%
JHG Janus Henderson 11.52M +5.21M +82.6%
JPM JPMorgan Chase & Co. 22.44M +4.49M +25.0%
BK Bank Of New York Mellon 18.59M +3.48M +23.0%
Two Sigma Advisers 2.6M -3.11M -54.4%
Vanguard 125.6M +3.03M +2.5%
Capital International Investors 7.97M -2.91M -26.7%

Financial report summary

  • The expiration or loss of patent protection and licenses may adversely affect AbbVie's future revenues and operating earnings.
  • AbbVie's major products could lose patent protection earlier than expected, which could adversely affect AbbVie's future revenues and operating earnings.
  • AbbVie's research and development efforts may not succeed in developing and marketing commercially successful products and technologies, which may cause its revenues and profitability to decline.
  • AbbVie's biologic products are subject to competition from biosimilars.
  • Significant safety or efficacy issues could arise for AbbVie's products, which could have a material adverse effect on AbbVie's revenues and financial condition.
  • AbbVie is subject to numerous governmental regulations, and it can be costly to comply with these regulations and to develop compliant products and processes.
  • AbbVie is dependent on wholesale distributors for distribution of its products in the United States and, accordingly, its results of operations could be adversely affected if they encounter financial difficulties.
  • AbbVie has debt obligations that could adversely affect its business and its ability to meet its obligations.
  • Failure to attract and retain highly qualified personnel could affect AbbVie’s ability to successfully develop and commercialize products.
  • The pending acquisition of Allergan may not be completed on the currently contemplated timeline or terms, or at all, and may not achieve the intended benefits.
  • The indebtedness of the combined company following the consummation of the Acquisition will be substantially greater than AbbVie’s indebtedness on a standalone basis and greater than the combined indebtedness of AbbVie and Allergan prior to the announcement of the acquisition. This increased level of indebtedness could adversely affect the combined company’s business flexibility and increase its borrowing costs.
Management Discussion
  • AbbVie's strategy has focused on delivering strong financial results, advancing and investing in its pipeline and returning value to shareholders while ensuring a strong, sustainable growth business over the long term. The company's financial performance in 2019 included delivering worldwide net revenues of $33.3 billion, operating earnings of $13.0 billion, diluted earnings per share of $5.28 and cash flows from operations of $13.3 billion. Worldwide net revenues grew by 3% on a constant currency basis, primarily driven by revenue growth related to IMBRUVICA and VENCLEXTA as well as the continued strength of HUMIRA in the U.S. and newly launched immunology assets SKYRIZI and RINVOQ, offset by international HUMIRA biosimilar competition.
Content analysis ?
H.S. freshman Avg
New words: agreed, allocation, AstraZeneca, auction, Award, azacitidine, brazikumab, calculated, capacity, Carlo, chain, confidence, consent, create, customer, cytarabine, decree, Director, diverse, divest, divestiture, donation, Dutch, EC, enhanced, essential, exocrine, experience, experimental, forecasted, hematologic, High, infrastructure, insufficiency, Interactive, intraperiod, inventory, leverage, mandatory, Monte, nature, Nestle, Organization, outbreak, page, pandemic, partnered, protect, PsA, Ratable, refiled, remote, removing, requisite, Retention, reverse, rituximab, RSU, shelter, simulation, small, spread, stage, strain, supply, swap, temporarily, tender, travel, troubled, unavailable, uncertain, uninterrupted, unpaid, VENCLYXTO, Venice, Viokace, weighted, XBRL, Zenpep
Removed: add, adjusted, adjustment, applied, arm, asserted, beginning, BELLINI, Boehringer, borrowing, Brown, capitalization, cell, charge, Cipla, classification, classified, collected, commence, commencing, competing, composition, consumer, covering, decision, declining, delivery, differentiate, Duodopa, enactment, enrollment, estate, exclude, expired, finance, formed, framework, GAZYVA, giant, greater, hold, implicit, improved, index, Ingelheim, initially, initiated, instituted, intended, inter, invalidity, investigational, Kabi, lease, maintenance, measurement, modified, motion, multiplied, Mutual, myeloma, NDA, observed, obtained, Ohio, ongoing, opening, optional, oral, package, paid, partial, phototherapy, point, practical, priority, proportion, PTO, RA, real, reclassification, recognize, redeemed, reflecting, renewal, repayment, residual, retrospective, review, reviewed, risankizumab, Rubinstein, separate, short, statement, Stemcentrx, stranded, Sublease, sustainability, systemic, tolerability, twelve, type, typically, Union, upadacitinib, USA